In vitro PK/PD modeling of tyrosine kinase inhibitors in non-small cell lung cancer cell lines.
Journal
Clinical and translational science
ISSN: 1752-8062
Titre abrégé: Clin Transl Sci
Pays: United States
ID NLM: 101474067
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
revised:
22
11
2023
received:
08
08
2023
accepted:
14
12
2023
medline:
13
3
2024
pubmed:
13
3
2024
entrez:
13
3
2024
Statut:
ppublish
Résumé
Tyrosine kinase inhibitors (TKIs) are routinely prescribed for the treatment of non-small cell lung cancer (NSCLC). As with all medications, patients can experience adverse events due to TKIs. Unfortunately, the relationship between many TKIs and the occurrence of certain adverse events remains unclear. There are limited in vivo studies which focus on TKIs and their effects on different regulation pathways. Many in vitro studies, however, that investigate the effects of TKIs observe additional changes, such as changes in gene activations or protein expressions. These studies could potentially help to gain greater understanding of the mechanisms for TKI induced adverse events. However, in order to utilize these pathways in a pharmacokinetic/pharmacodynamic (PK/PD) framework, an in vitro PK/PD model needs to be developed, in order to characterize the effects of TKIs in NSCLC cell lines. Through the use of ordinary differential equations, cell viability data and nonlinear mixed effects modeling, an in vitro TKI PK/PD model was developed with estimated PK and PD parameter values for the TKIs alectinib, crizotinib, erlotinib, and gefitinib. The relative standard errors for the population parameters are all less than 25%. The inclusion of random effects enabled the model to predict individual parameter values which provided a closer fit to the observed response. It is hoped that this model can be extended to include in vitro data of certain pathways that may potentially be linked with adverse events and provide a better understanding of TKI-induced adverse events.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13714Informations de copyright
© 2024 The Authors. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics.
Références
Yuan M, Huang LL, Chen JH, Wu J, Xu Q. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer. Sig Transduct Target Ther. 2019;4:61.
Chan BA, Hughes BG. Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res. 2015;4(1):36-54.
Hall Richard D, Le Tri M, Haggstrom Daniel E, Gentzler Ryan D. Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC). Transl Lung Cancer Res. 2015;4(5):515-523.
Franklin W, Veve R, Hirsch F, Helfrich B, Bunn P. Epidermal growth factor receptor family in lung cancer and premalignancy. Semin Oncol. 2002;29(1):3-14.
Saraon P, Pathmanathan S, Snider J, Lyakisheva A, Wong V, Staglijar I. Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches. Oncogene. 2021;40:4079-4093.
Cancer Therapy Evaluation Program. Protocol development website. Accessed 15 June, 2023. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm
Ota S, Matsukawa T, Yamamoto S, et al. Severe adverse events by tyrosine kinase inhibitors decrease survival rates in patients with newly diagnosed chronic-phase chronic myeloid leukemia. Eur J Haematol. 2018;101(1):95-105.
Nawa H, Niimura T, Hamano H, et al. Evaluation of potential complications of interstitial lung disease associated with antiandrogens using data from databases reporting spontaneous adverse effects. Front Pharmacol. 2021;12:655605.
Rana P, Aleo MD, Wen X, Kogut S. Hepatotoxicity reports in the FDA adverse event reporting system database: a comparison of drugs that cause injury via mitochondrial or other mechanisms. Acta Pharm. Sin. B. 2021;11(12):3857-3868.
Schwendimann R, Blatter C, Dhaini S, Simon M, Ausserhofer D. The occurrence, types, consequences and preventability of in-hospital adverse events - a scoping review. BMC Health Serv Res. 2018;18(1):521.
Santomasso BD, Nastoupil LJ, Adkins S, et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J Clin Oncol. 2021;39(35):3978-3992.
Kim M, Yang YS, Ko Y, Choi M. Major adverse events in patients with peripheral artery disease after endovascular revascularization: a retrospective study. J Clin Med. 2022;11(9):2547.
Kawase S, Hattori N, Ishikawa N, et al. Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung disease. Respir Res. 2011;12:97.
Valeyrie L, Bastuji-Garin S, Revuz J, et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol. 2003;48(2):201-206.
Lenihan DJ, Kowey PR. Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors. Oncologist. 2013;18(8):900-908.
Kogita A, Togashi Y, Hayashi H, et al. Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer. Int J Oncol. 2014;46(3):1025-1030.
Zhang X, Liu G, Kang Y, Dong Z, Qian Q, Ma X. N-cadherin expression is associated with acquisition of EMT phenotype and with enhanced invasion in Erlotinib-resistant lung cancer cell lines. PloS One. 2013;8(3):e57692.
National Center Biotechnology Information (NCBI). GEO, Series GSE116442 website. Accessed 15 June, 2023. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE116442
National Center Biotechnology Information (NCBI). GEO, Series GSE34228 website. Accessed 15 June, 2023. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE34228
Saito A, Horie M, Nagase T. TGF-β signaling in lung health and disease. Int J Mol Sci. 2018;19(8):2460.
Salahudeen MS, Nishtala PS. An overview of pharmacodynamic modelling, ligand-binding approach and its application in clinical practice. Saudi Pharm J. 2017;25(2):165-175.
Rohatgi A. Web Plot Digitizer website. Accessed 15 June, 2023. https://automeris.io/WebPlotDigitizer
Schneider CA, Rasband WS, Eliceiri KW. NIH image to ImageJ: 25 years of image analysis. Nat Methods. 2012;9(7):671-675.
Nykamp D. An introduction to ordinary differential equations - Math Insight website. Accessed 15 June, 2023. https://mathinsight.org/ordinary_differential_equation_ introduction
Metibemu DS, Akinloye OA, Akamo AJ, Ojo DO, Okeowo OT, Omotuyi IO. Exploring receptor tyrosine kinases-inhibitors in cancer treatments. Egypt J Med Hum Genet. 2019;20(1):20-35.
Dayneka NL, Garg V, Jusko WJ. Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm. 1993;21(4):457-478.
Thermofisher. Useful numbers for cell culture. Thermo Fisher Scientific - UK website. Accessed 15 June, 2023. https://www.thermofisher.com/uk/en/home/references/gibco-cell-culture-basics/cell-culture-protocols/cell-culture-useful-numbers.html
Yates J, Evans N, Chappell M. Structural identifiability analysis via symmetries of differential equations. Automatica. 2009;45(11):2585-2591.
Janzén D, Jirstrand M, Chappell M, Evans N. Three novel approaches to structural identifiability analysis in mixed-effects models. Comput Methods Programs Biomed. 2019;171:141-152.
Janzén D, Jirstrand M, Chappell M, Evans N. Extending existing structural identifiability analysis methods to mixed-effects models. Math Biosci. 2018;295:1-10.
Bearup D, Evans N, Chappell M. The input-output relationship approach to structural Identifiability analysis. UKACC International Conference on CONTROL 2010.
Chis O, Banga J, Balsa-Canto E. Structural Identifiability of systems biology models: a critical comparison of methods. PloS One. 2011;6(11):e27755.
Wolfram Research, Inc. Mathematica, Version 13.0.0, Champaign, IL. 2021.
Monagan MB, Geddes KO, Heal KM, Labahn G, Vorkoetter S, Devitt J. Maple V Programming Guide: For Release 5. Springer Science & Business Media. Accessed: July 2022. https://www.maplesoft.com/products/Maple/; 2012.
Jarrett AM, Liu Y, Cogan NG, Hussaini MY. Global sensitivity analysis used to interpret biological experimental results. J Math Biol. 2015;71:151-170.
Nossent J, Elsen P, Bauwens W. Sobol’ sensitivity analysis of a complex environmental model. Environ Model Softw. 2011;26(12):1515-1525.
R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2022. website. Accessed 15 June, 2023. https://www.R-project.org/
Weber F, Theers S. ODEsensitivity: Sensitivity analysis of ordinary differential equations. R package version 1.1.2 website. Accessed 15 June, 2023. https://CRAN.R-project.org/package=ODEsensitivity
Surmann D. ODEnetwork: Network of differential equations_ R package version 1.3.2 website. Accessed 15 June, 2023. https://CRAN.R-project.org/package=ODEnetwork
Monolix version 2019R1. Antony, France: Lixoft SAS website. Accessed 15 June, 2023. http://lixoft.com/products/monolix/
Lixoft, Monolix methodology version 4.3.3 website. Accessed 15 June, 2023. http://lixoft.com/wp-content/ uploads/2016/03/monolixMethodology.pdf
Gabrielsson J, Andersson R, Jirstrand M, Hjorth S. Dose-response-time data analysis: an underexploited trinity. Pharmacol Rev. 2018;71(1):89-122.
TARCEVA. Accessdata.fda.gov website. (erlotinib) FDA. Accessed 15 June, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/021743s14s16lbl.pdf
Gefitinib FDA. Accessdata***.fda.gov website. Accessed 15 June, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/206995orig1s000clinpharmr.pdf
ALENCESA. Accessdata***.fda.gov website. (alectinib) FDA. Accessed 15 June, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208434s001lbl.pdf
XALKORI. Accessdata***.fda.gov website. (crizotinib) FDA. Accessed 15 June, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/202570s030lbl.pdf
Eigenmann MJ, Frances N, Hoffmann G, Lavé T, Walz A. Combining nonclinical experiments with translational PKPD modeling to differentiate erlotinib and gefitinib. Mol Cancer Ther. 2016;15(12):3110-3119.
Xu W, Wu W, Zhang D, et al. A novel CT scoring method predicts the prognosis of interstitial lung disease associated with anti-MDA5 positive dermatomyositis. Sci Rep. 2021;11:17070.
Exarchos KP, Gkrepi G, Kostikas K, Gogali A. Recent advances of artificial intelligence applications in interstitial lung diseases. Diagnostics. 2023;13(13):2303.
Zhang J, Qiu T, Zhou Y, Wu S, Chen E. Tyrosine kinase inhibitors-associated interstitial lung disease used in non-small cell lung cancer: a pharmacovigilance analysis based on the FDA adverse event reporting system database. Expert Opin Drug Saf. 2023;22(9):849-856.